HealthSport's bi-layer edible film strip technology related patent application receives Mexican approval

HealthSport, Inc. (OTC Bulletin Board: HSPO), the preeminent formulator and developer of edible, multi-layer film strips that deliver drug and dietary supplement actives through buccal and sublingual absorption as well as oral ingestion, announced today that the Mexican Institute of Industrial Property has approved HealthSport's patent application relating to its bi-layer edible film strip technology.  

The patent issuance opens the door for sales and distribution into Mexico, and is expected to accelerate HealthSport's move into the international marketplace.  The Mexican market for OTC drugs is larger than that of China and is a natural next step into international sales and distribution of HealthSport's products.  

The issuance of the Mexican patent also strengthens HealthSports's commitment to develop products based on it's next-generation drug delivery technology.

"We have long recognized the unique value that our film strip technology can provide to consumers through a number of different products, and the recently issued Mexican patent reinforces this belief, further demonstrating the proprietary nature of our technology."  

HealthSport currently has seven additional patent applications pending in the U.S. and several other countries.

Source:

HealthSport, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Aptamer extends agreement with genetic medicines customer